These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35801486)

  • 1. Design, synthesis and molecular docking of new fused 1
    Belal A; Abdel Gawad NM; Mehany ABM; Abourehab MAS; Elkady H; Al-Karmalawy AA; Ismael AS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1884-1902. PubMed ID: 35801486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
    Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
    Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA
    Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
    Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
    Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
    Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
    Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
    Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation, and
    Mandour AA; Nassar IF; Abdel Aal MT; Shahin MAE; El-Sayed WA; Hegazy M; Yehia AM; Ismail A; Hagras M; Elkaeed EB; Refaat HM; Ismail NSM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1957-1973. PubMed ID: 35815597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer activity evaluation of some novel pyrrolo[1,2-a]azepine derivatives.
    Belal A
    Arch Pharm (Weinheim); 2014 Jul; 347(7):515-22. PubMed ID: 24729464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
    Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
    Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Novel Class of Phenylpyrazolo[3,4-
    Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.